Easywell Biomedicals, Inc.

1799

TW0001799005

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
74.3 ^TWD	+0.41%		-0.93%	+79.90%

08/05	Easywell Biomedicals, Inc. announced a financing transaction	CI
07/04	Easywell Biomedicals, Inc.'s Subsidiary Jiangsu Huahan Pharma-Tech Co., Ltd. Obtains Approval from the Jiangsu Medical Products Administration of China for Compliance with the Good Manufacturing Practice Inspection for Pharmaceuticals	CI

Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020

March 30, 2021 at 03:15 am IST

Easywell Biomedicals, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 267.654 million compared to TWD 359.960 million a year ago. Operating loss was TWD 158.860 million compared to TWD 215.972 million a year ago. Net loss was TWD 173.412 million compared to TWD 271.797 million a year ago.

Latest news about Easywell Biomedicals, Inc.

Easywell Biomedicals, Inc. announced a financing transaction	08/05	CI
Easywell Biomedicals, Inc.'s Subsidiary Jiangsu Huahan Pharma-Tech Co., Ltd. Obtains Approval from the Jiangsu Medical Products Administration of China for Compliance with the Good Manufacturing Practice Inspection for Pharmaceuticals	07/04	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/22/31	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	30/21/30	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	12/20/12	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	12/20/12	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	14/20/14	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	30/20/30	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	13/19/13	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/19/14	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	14/19/14	CI
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	28/19/28	CI
Easywell Biomedicals, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	13/18/13	CI

Chart Easywell Biomedicals, Inc.

Duration

Period

More charts

Company Profile

Easywell Biomedicals Inc. is a Taiwan-based company principally engaged in the research, development, production and sale of raw materials and temperature measurement products. The raw materials are applied in the manufacture of medicament for the treatment of epilepsy, pain and fever, antihypertensive and diuretic, skeletal muscle relaxants, among others. The Company's diagnostic devices include ear thermometers and digital clinical thermometers. The Company distributes its products mainly in Taiwan, the Americas and Europe.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EASYWELL BIOMEDICALS, INC.	+79.90%	28Cr
NOVO NORDISK A/S	+31.49%	59TCr
JOHNSON & JOHNSON	-3.39%	36TCr
MERCK & CO., INC.	+19.26%	33TCr
ABBVIE INC.	+5.20%	29TCr
ASTRAZENECA PLC	+15.36%	24TCr
NOVARTIS AG	+9.99%	21TCr
ROCHE HOLDING AG	-6.91%	20TCr
AMGEN INC.	+9.97%	17TCr
PFIZER, INC.	-0.50%	16TCr

Other Pharmaceuticals